Israeli Company Says Worlds First COVID-19 Vaccine PILL Is On It’s Way

 Israeli Company Says Worlds First COVID-19 Vaccine PILL Is On It’s Way.

An Israeli-American pharmaceutical company is preparing to launch a Phase I clinical trial for what could become the world’s first oral COVID-19 vaccine.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company based on technology developed by Hadassah-University Medical Center, announced over the weekend a joint venture with Premas Biotech to develop a novel oral vaccine. Together they formed the company Oravax Medical Inc. The vaccine is based on Oramed’s “POD” oral delivery technology and Premas’s vaccine technology.

Oramed’s technology can be used to orally administer a number of protein-based therapies, which would otherwise be delivered by injection. Oramed is in the midst of a Phase III clinical trial through the US Food and Drug Administration of an oral insulin capsule for type I and types II diabetics.

It is understood that Premas has been working on developing a vaccine against the novel coronavirus since March. The companies connected earlier this year, according to Oramed CEO Nadav Kidron, and quickly realised that they could revolutionize the marketplace.

“An oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to take the vaccine themselves at home,” Kidron said. “While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot.”

It is still mandatory to wear masks during the pandemic, Amazon has a great range in stock, click on the link to see what they have on offer. https://amzn.to/3826Rmr

Thank you for taking the time to read this news article “ Israeli Company Says Worlds First COVID-19 Vaccine PILL Is On It’s Way”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.